EU nod for Bimzelx for moderate to severe plaque psoriasis
The approval is supported by three pivotal Phase III trials
Read More
Tag: plaque psoriasis
Interim trial data for UCB’s bimekizumab shows positive results
High levels of skin clearance achieved for moderate to severe plaque psoriasis patients
Read More
Cosentyx approved to treat plaque psoriasis in paediatric patients
IL-17A inhibitor has been cleared in the US to treat plaque psoriasis in certain patients aged six years and older
Read More
Amgen looks to expand access to Otezla in the US
Company has submitted a supplemental new drug application for mild-to-moderate plaque psoriasis
Read More
UCB’s bimekizumab data in plaque psoriasis published in The Lancet
Phase III BE VIVID and BE READY studies both met their co-primary endpoints
Read More
US expands scope of Janssen’s Stelara
The new approval cover paediatric patients with plaque psoriasis
Read More
Cosentyx successful in plaque psoriasis trial
The drug successfully modulates gene expression, leading to substantial improvement of inflammation.
Read More
NICE final guidance published for Cimzia
For adults who have failed to respond to, or are unsuitable for, other systemic therapies.
Read More
Study shows long-term efficacy for Ilumya in psoriasis
Sun Pharma’s Ilumya has proven to be efficient for up to three years of ongoing treatment.
Read More
Tremfya gets FDA approval in moderate-to-severe plaque psoriasis
Janssen has announced FDA approval of its novel drug Tremfya for adults with moderate-to-severe plaque psoriasis.
Read More
Ortho resubmits Duobrii in the US
Bausch Health group Ortho Dermatologics has resubmitted an application to market its plaque psoriasis lotion Duobrii in the US
Read More
Janssen’s Tremfya backed for NHS use
Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
